Pilot evaluation of paroxetine for treating hot flashes in men

Charles Lawrence Loprinzi, Debra L. Barton, Lisa A. Carpenter, Jeff A Sloan, Paul J. Novotny, Matthew T. Gettman, Bradley J. Christensen

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

OBJECTIVE: To provide prospective information on the potential utility of paroxetine for treating hot flashes in men receiving androgen ablation therapy for prostate cancer. PATIENTS AND METHODS: Men with symptomatic androgen ablation therapy-related hot flashes were entered into this clinical trial between August 2001 and October 2003. After a baseline week of documentation of the frequency of hot flashes, patients were assigned to receive paroxetine; the initial dosage was 12.5 mg/d, and it was increased to 37.5 mg/d over the ensuing 4 weeks. RESULTS: Of the 24 patients in whom medication was initiated, 18 completed the 5-week study. In these patients, the median frequency of hot flashes decreased from 6.2 per day during the baseline week to 2.5 per day during the last study week. Hot flash scores (frequency × mean severity) during the same period decreased from 10.6 per day to 3.0 per day. Overall, paroxetine was well tolerated by most patients. CONCLUSION: The results from this trial suggest that paroxetine is an effective agent for diminishing hot flashes in men receiving androgen ablation therapy.

Original languageEnglish (US)
Pages (from-to)1247-1251
Number of pages5
JournalMayo Clinic Proceedings
Volume79
Issue number10
StatePublished - 2004

Fingerprint

Hot Flashes
Paroxetine
Androgens
Documentation
Prostatic Neoplasms
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Loprinzi, C. L., Barton, D. L., Carpenter, L. A., Sloan, J. A., Novotny, P. J., Gettman, M. T., & Christensen, B. J. (2004). Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clinic Proceedings, 79(10), 1247-1251.

Pilot evaluation of paroxetine for treating hot flashes in men. / Loprinzi, Charles Lawrence; Barton, Debra L.; Carpenter, Lisa A.; Sloan, Jeff A; Novotny, Paul J.; Gettman, Matthew T.; Christensen, Bradley J.

In: Mayo Clinic Proceedings, Vol. 79, No. 10, 2004, p. 1247-1251.

Research output: Contribution to journalArticle

Loprinzi, CL, Barton, DL, Carpenter, LA, Sloan, JA, Novotny, PJ, Gettman, MT & Christensen, BJ 2004, 'Pilot evaluation of paroxetine for treating hot flashes in men', Mayo Clinic Proceedings, vol. 79, no. 10, pp. 1247-1251.
Loprinzi CL, Barton DL, Carpenter LA, Sloan JA, Novotny PJ, Gettman MT et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clinic Proceedings. 2004;79(10):1247-1251.
Loprinzi, Charles Lawrence ; Barton, Debra L. ; Carpenter, Lisa A. ; Sloan, Jeff A ; Novotny, Paul J. ; Gettman, Matthew T. ; Christensen, Bradley J. / Pilot evaluation of paroxetine for treating hot flashes in men. In: Mayo Clinic Proceedings. 2004 ; Vol. 79, No. 10. pp. 1247-1251.
@article{1146b6c9f7bf40efaf72c26586c556a4,
title = "Pilot evaluation of paroxetine for treating hot flashes in men",
abstract = "OBJECTIVE: To provide prospective information on the potential utility of paroxetine for treating hot flashes in men receiving androgen ablation therapy for prostate cancer. PATIENTS AND METHODS: Men with symptomatic androgen ablation therapy-related hot flashes were entered into this clinical trial between August 2001 and October 2003. After a baseline week of documentation of the frequency of hot flashes, patients were assigned to receive paroxetine; the initial dosage was 12.5 mg/d, and it was increased to 37.5 mg/d over the ensuing 4 weeks. RESULTS: Of the 24 patients in whom medication was initiated, 18 completed the 5-week study. In these patients, the median frequency of hot flashes decreased from 6.2 per day during the baseline week to 2.5 per day during the last study week. Hot flash scores (frequency × mean severity) during the same period decreased from 10.6 per day to 3.0 per day. Overall, paroxetine was well tolerated by most patients. CONCLUSION: The results from this trial suggest that paroxetine is an effective agent for diminishing hot flashes in men receiving androgen ablation therapy.",
author = "Loprinzi, {Charles Lawrence} and Barton, {Debra L.} and Carpenter, {Lisa A.} and Sloan, {Jeff A} and Novotny, {Paul J.} and Gettman, {Matthew T.} and Christensen, {Bradley J.}",
year = "2004",
language = "English (US)",
volume = "79",
pages = "1247--1251",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Pilot evaluation of paroxetine for treating hot flashes in men

AU - Loprinzi, Charles Lawrence

AU - Barton, Debra L.

AU - Carpenter, Lisa A.

AU - Sloan, Jeff A

AU - Novotny, Paul J.

AU - Gettman, Matthew T.

AU - Christensen, Bradley J.

PY - 2004

Y1 - 2004

N2 - OBJECTIVE: To provide prospective information on the potential utility of paroxetine for treating hot flashes in men receiving androgen ablation therapy for prostate cancer. PATIENTS AND METHODS: Men with symptomatic androgen ablation therapy-related hot flashes were entered into this clinical trial between August 2001 and October 2003. After a baseline week of documentation of the frequency of hot flashes, patients were assigned to receive paroxetine; the initial dosage was 12.5 mg/d, and it was increased to 37.5 mg/d over the ensuing 4 weeks. RESULTS: Of the 24 patients in whom medication was initiated, 18 completed the 5-week study. In these patients, the median frequency of hot flashes decreased from 6.2 per day during the baseline week to 2.5 per day during the last study week. Hot flash scores (frequency × mean severity) during the same period decreased from 10.6 per day to 3.0 per day. Overall, paroxetine was well tolerated by most patients. CONCLUSION: The results from this trial suggest that paroxetine is an effective agent for diminishing hot flashes in men receiving androgen ablation therapy.

AB - OBJECTIVE: To provide prospective information on the potential utility of paroxetine for treating hot flashes in men receiving androgen ablation therapy for prostate cancer. PATIENTS AND METHODS: Men with symptomatic androgen ablation therapy-related hot flashes were entered into this clinical trial between August 2001 and October 2003. After a baseline week of documentation of the frequency of hot flashes, patients were assigned to receive paroxetine; the initial dosage was 12.5 mg/d, and it was increased to 37.5 mg/d over the ensuing 4 weeks. RESULTS: Of the 24 patients in whom medication was initiated, 18 completed the 5-week study. In these patients, the median frequency of hot flashes decreased from 6.2 per day during the baseline week to 2.5 per day during the last study week. Hot flash scores (frequency × mean severity) during the same period decreased from 10.6 per day to 3.0 per day. Overall, paroxetine was well tolerated by most patients. CONCLUSION: The results from this trial suggest that paroxetine is an effective agent for diminishing hot flashes in men receiving androgen ablation therapy.

UR - http://www.scopus.com/inward/record.url?scp=4644308164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644308164&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 1247

EP - 1251

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -